BiotechTube

REC-2282 + Placebo

Phase 2/3Terminated
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis Type 2

Conditions

Neurofibromatosis Type 2

Trial Timeline

Jun 20, 2022 → Aug 18, 2025

NCT ID
NCT05130866

About REC-2282 + Placebo

REC-2282 + Placebo is a phase 2/3 stage product being developed by Recursion Pharmaceuticals for Neurofibromatosis Type 2. The current trial status is terminated. This product is registered under clinical trial identifier NCT05130866. Target conditions include Neurofibromatosis Type 2.

What happened to similar drugs?

0 of 1 similar drugs in Neurofibromatosis Type 2 were approved

Approved (0) Terminated (0) Active (1)
🔄SelumetinibAstraZenecaPhase 3

Hype Score Breakdown

Clinical
15
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05130866Phase 2/3Terminated

Competing Products

20 competing products in Neurofibromatosis Type 2

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
27
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
29
AZD2014AstraZenecaPhase 2
35
Selumetinib + PlaceboAstraZenecaPhase 2
27
Treatment A + Treatment B + Treatment C + Treatment D + AcetaminophenAstraZenecaPhase 1
29
SelumetinibAstraZenecaPhase 1/2
32
SelumetinibAstraZenecaPhase 1
33
Selumetinib granule formulation + Selumetinib capsule formulationAstraZenecaPhase 1/2
36
SelumetinibAstraZenecaPhase 3
44
Everolimus (RAD001) , Afinitor®NovartisPhase 2
35
RAD001: EverolimusNovartisPhase 2
35
RAD001, everolimusNovartisPhase 2
27
TasignaNovartisPhase 1
29
TrametinibNovartisPhase 2
39
Everolimus (RAD001)NovartisPhase 2
27
Sutent®/SunitinibPfizerPhase 2
27
Sorafenib (Nexavar)BayerPhase 2
24
PTC299United TherapeuticsPhase 2
24
BinimetinibPacific BiosciencesPhase 2
25